Posted by Michael Wonder on 20 Dec 2024
PTC Therapeutics announces vatiquinone NDA submission to FDA for the treatment of children and adults living with Friedreich ataxia
19 December 2024 - PTC's fourth approval application submitted to FDA in 2024.
PTC Therapeutics announced today the submission of the vatiquinone new drug application for the treatment of children and adults living with Friedreich ataxia to the US FDA.
